Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q04609

UPID:
FOLH1_HUMAN

ALTERNATIVE NAMES:
Cell growth-inhibiting gene 27 protein; Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; Glutamate carboxypeptidase II; Membrane glutamate carboxypeptidase; N-acetylated-alpha-linked acidic dipeptidase I; Prostate-specific membrane antigen; Pteroylpoly-gamma-glutamate carboxypeptidase

ALTERNATIVE UPACC:
Q04609; A4UU12; A9CB79; B7Z312; B7Z343; D3DQS5; E9PDX8; O43748; Q16305; Q541A4; Q8TAY3; Q9NP15; Q9NYE2; Q9P1P8

BACKGROUND:
Glutamate carboxypeptidase 2, also known as Prostate-specific membrane antigen, plays a pivotal role in the hydrolysis of neuropeptides and folate absorption. Its enzymatic activities, including the cleavage of tri-alpha-glutamate peptides and Gly-Pro-AMC, underline its significance in neurotransmitter release and nutrient uptake, marking it as a key player in prostate tumor progression and brain function.

THERAPEUTIC SIGNIFICANCE:
The exploration of Glutamate carboxypeptidase 2's functions offers promising avenues for therapeutic intervention. Its dual role in neurotransmitter regulation and nutrient metabolism makes it a potential target for addressing prostate cancer progression and disorders related to folate deficiency or neurotransmitter imbalance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.